Anzeige
Mehr »
Login
Mittwoch, 04.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Analysten eilen, um Kursziele zu verdreifachen nach ATHAs neuester Entdeckung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QLR3 | ISIN: US98422P1084 | Ticker-Symbol: 8HX
Tradegate
03.12.24
12:25 Uhr
0,720 Euro
-0,095
-11,66 %
Branche
Handel/E-Commerce
Aktienmarkt
ASIEN
1-Jahres-Chart
AKSO HEALTH GROUP ADR Chart 1 Jahr
5-Tage-Chart
AKSO HEALTH GROUP ADR 5-Tage-Chart
RealtimeGeldBriefZeit
0,8000,84009:16
0,8000,84008:31
GlobeNewswire (Europe)
329 Leser
Artikel bewerten:
(1)

Akso Health Group: AHG Announces Plan to Acquire Online Clinic

Finanznachrichten News

QINGDAO CHINA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Akso Health Group (NASDAQ: AHG) ( "Akso Health," "the Company," or "we") today announced its plan to make an equity investment in Deyihui, an online clinic based in China.

Akso Health plans to tap into the online clinic business initially in China and if the results are satisfactory, to expand this business to the other countries and regions. Given the rapid growth of virtual consultations in mainland China, management believes this is a significant untapped market where the Company may leverage its capital resources as well as first-move advantage. The planned equity investment in Deyuhui is expected to aid management in getting familiar with the online clinic business.

Ms. Yilin Wang, Chairwoman and CEO of Akso Health, commented, "Our ambition is to build a comprehensive medical technology service platform providing reliable, and efficient healthcare services." This move marks Akso Health's active engagement in the development of Internet smart healthcare services.

About Akso Health Group

Akso Health Group (NASDAQ: AHG), formerly known as Xiaobai Maimai Inc., operates a social e-commerce platform in China that collaborates with other domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products. Since the end of 2021, the Company started exploring the healthcare equipment and product trading and related healthcare services business.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "potential," "continue," "ongoing," "targets," "guidance" and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements that involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors and risks include, but not limited to the following: risks related to our ability to obtain equipment, technology, license and talents at satisfactory terms to grow the medical equipment business and/or to start the planned healthcare business, if at all; risks regarding the effect of the COVID-19 pandemic on the Company and the Company's position in a post-COVID-19 environment; risks related to the Company's ability to adapt and make the necessary adjustments to compete and operate effectively; risks related to decisions or changes in governmental policies in the healthcare segment; risks related to increased competition and the development of new competing services; the risk that we may be unable to develop or achieve commercial success for our medical and healthcare services in a timely manner, or at all; risks related to regulatory requirements or enforcement in relevant jurisdiction and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to successfully integrate and derive benefits from any technologies that we license or acquire; risks related to our projections about our business, results of operations and financial condition; and risks related to the potential market opportunity for our products and services. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC. All information provided in this announcement is current as of the date of this announcement, and the Company does not undertake any obligation to update such information, except as required under applicable law.

For more information, please visit http://www.ahgtop.com/en/index.html

For investor inquiries, please contact:

Akso Health Group
Investor Relations
Email: ir@ahgtop.com


© 2024 GlobeNewswire (Europe)
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.